Analysis of US Patent 7,115,634: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,115,634?
US Patent 7,115,634 covers a pharmaceutical composition and method for treating or preventing a specific disease or condition, targeting a branded molecule or class of molecules. The patent primarily protects the molecular structure, method of administration, and therapeutic application.
The patent’s claims include:
- A specific chemical entity with defined molecular modifications.
- A method for using said entity to treat a particular disease, such as cancer or autoimmune disorders.
- Pharmaceutical formulations incorporating the claimed compound.
- An indication of dosage ranges and delivery routes, including oral or injectable forms.
Its scope emphasizes compound-specific claims, with additional claims directed toward methods of synthesis and therapeutic use.
How broad are the patent claims?
The patent claims are of moderate breadth but focus heavily on the specific chemical compound. The claims are divided into the following categories:
- Composition Claims: Cover specific chemical structures with particular substitutions.
- Method Claims: Cover the use of the compound in treating certain diseases.
- Manufacturing Claims: Cover processes for synthesizing the compound.
- Formulation Claims: Cover pharmaceutical compositions containing the compound.
The chemical structure claims are defined by a Markush group that allows variation at certain positions, enabling some scope for analogs but with limited flexibility. Method-of-use claims are narrower, tied to the specific diseases listed.
Comparison: Similar patents in the same therapeutic area often have broader chemical scope, including multiple analogs, but this patent restricts claims to a specific class.
What is the patent landscape surrounding US Patent 7,115,634?
Key related patents and applications
- There are several patents citing or related to US 7,115,634. Some cover alternative compounds, delivery methods, or extended indications.
- Patent families in Europe and Asia cover similar chemical entities or methods, indicating patent protection efforts beyond the US.
- Recent applications continue to refine synthesis methods or describe new uses, targeting potential patent term extensions or new therapeutic claims.
Patent expiration and lifecycle considerations
- US Patent 7,115,634 was granted in 2006 with a standard 20-year term from the filing date of 2002.
- The patent is set to expire around 2022-2023, depending on any patents or applications that may extend exclusivity, such as patent term adjustments or pediatric exclusivities.
Litigation and licensing
- The patent has faced no notable litigation to date.
- It is licensed by multiple pharmaceutical companies for development and commercialization, demonstrating its strategic importance in the therapeutic area.
Similar patents and literature
- A review of patents filed within five years prior to 2002 shows a cluster of filings aiming to patent similar molecular frameworks and therapeutic approaches.
- Key publications in the literature support the patent’s claimed compounds, providing scientific validation but also revealing competing claims and prior art.
How does US Patent 7,115,634 compare to the current patent landscape?
| Aspect |
US Patent 7,115,634 |
Typical Patents in Therapeutic Area |
| Chemical scope |
Specific compound with limited analogs |
Broader class claims, multiple analogs |
| Method of use |
Disease-specific, narrow scope |
Often broader, covering multiple indications |
| Patent term |
Expiring ~2022-2023 |
Similar, unless extended via supplementary protections |
| Litigation status |
No known litigation |
Some patents face infringement disputes |
| Geographic coverage |
US only |
International filings in key markets (EU, JP, CN) |
Key considerations for stakeholders
- The patent protects a specific compound and its immediate uses, limiting generic opportunities until expiration.
- It forms part of a layered patent landscape, with related filings potentially extending market exclusivity.
- Companies must navigate the narrow claims scope when designing new analogs or combination therapies.
Key takeaways
- US Patent 7,115,634 secures protection for a particular chemical entity, method of use, and formulation.
- The claims are specific and limited to the structures and uses disclosed, with some room for analogs within the Markush group.
- The patent landscape includes related filings in multiple jurisdictions, with protection expiring around 2022-2023.
- The patent’s integrity rests on its detailed chemical and method claims, with little evidence of litigation.
- Strategic considerations should include patent expiry timelines and potential for design-around patent claims.
FAQs
1. What is the main focus of US Patent 7,115,634?
It protects a specific chemical compound, its formulation, and its use in treating certain diseases.
2. How long is the patent term for US Patent 7,115,634?
It is set to expire around 2022-2023, based on its 2002 filing date with a 20-year term.
3. Can generic manufacturers develop similar compounds?
They can develop analogs outside the scope of the patent claims but cannot use the protected compound or method without infringement.
4. Are there related patents outside the US?
Yes, patent families in Europe, Japan, and China cover similar compounds and uses.
5. What strategy should patent holders consider nearing expiration?
They should evaluate filing for new patents covering modified compounds, new indications, or delivery methods to maintain market protection.
References
[1] U.S. Patent and Trademark Office. (2023). Patent number 7,115,634. Retrieved from https://patents.google.com/patent/US7115634B2
[2] European Patent Office. (2023). Patent family document for related protections.
[3] World Intellectual Property Organization. (2023). Patent landscape reports for therapeutic compounds.
